Cargando…
PSUN68 Finerenone for Primary Aldosteronism: A Novel Mineralocorticoid Receptor Antagonist
BACKGROUND: In primary aldosteronism (PA), aldosterone is inappropriately released into the systemic circulation and binds to the mineralocorticoid receptor (MR) in the distal tubule and collecting duct of the kidney. As a result, there is sodium reabsorption and potassium wasting leading to extrace...
Autores principales: | Aurora, John, Alpertunga, Ipek, Siegel, Richard, Lechan, Ronald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624847/ http://dx.doi.org/10.1210/jendso/bvac150.529 |
Ejemplares similares
-
SAT-561 Effects of Mineralocorticoid Receptor Antagonists on Primary Aldosteronism Screening
por: Tezuka, Yuta, et al.
Publicado: (2020) -
PSUN53 Using Renin Activity to Guide Mineralocorticoid Receptor Antagonist Therapy in Patients with Low-Renin Hypertension
por: Mansur, Arian, et al.
Publicado: (2022) -
Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
por: Tezuka, Yuta, et al.
Publicado: (2021) -
The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023) -
SAT-564 Effectiveness of Treatment with Mineralocorticoid Receptor Antagonistsin Primary Aldosteronism
por: Tezuka, Yuta, et al.
Publicado: (2020)